Related Experiment Video
Updated: May 1, 2026

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.7K
Summary
Emergency hospital admissions are a major concern, especially for people with diabetes who face double the risk. New guidance provides best-practice solutions to help reduce these unsustainable admissions and improve healthcare capacity.
Area of Science:
- Public Health
- Healthcare Management
- Diabetes Care
Background:
- Rising emergency hospital admissions pose a significant challenge to the National Health Service (NHS).
- These admissions negatively affect elective surgery capacity and patient waiting times, creating an unsustainable healthcare system.
- Individuals with diabetes have a nearly twofold higher risk of hospitalization compared to the general population.
Purpose of the Study:
- To highlight the urgent need for the National Health Service (NHS) to address the increasing trend of emergency hospital admissions.
- To emphasize the disproportionate risk of hospitalization faced by individuals with diabetes.
- To introduce new guidance offering best-practice solutions for commissioners to manage diabetes-related admissions.
Main Methods:
- Review of current NHS priorities and challenges related to emergency admissions.
- Analysis of risk factors for hospitalization, with a focus on diabetes prevalence.
- Identification and synthesis of best-practice solutions from new guidance for healthcare commissioners.
Main Results:
- Emergency hospital admissions are unsustainable and impact NHS elective capacity.
- People with diabetes are at significantly higher risk of hospitalization.
- New guidance provides actionable strategies for commissioners to tackle diabetes-related admissions.
Conclusions:
- Reducing emergency hospital admissions is a critical NHS priority.
- Targeted interventions for diabetes care are essential to mitigate hospitalization risks.
- Implementing the new guidance can lead to improved patient outcomes and more efficient healthcare resource allocation.
Related Concept Videos
Diabetes: Management and Pharmacotherapy
1.5K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.5K
Diabetes Mellitus: Type 2 and Gestational
4.9K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.9K
Dipeptidyl Peptidase 4 Inhibitors
1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
Diabetes: Symptoms, Diagnosis, and Complications
2.5K
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
2.5K
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
17
Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated...
17
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
953
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
953

